News | News By Subject | News by Disease News By Date | Search News

Melanoma News Articles

Get Our FREE
Industry eNewsletter
email:    
Top Breaking News
Two Deaths Linked to Bristol-Myers Squibb (BMY)'s Yervoy-Opdivo Combo     11/3/2016
Scancell (SCNLF) Delays Melanoma Trial 9 to 12 Months to Whip Up New Batch of Cancer Vaccine     7/7/2016
Scancell (SCNLF) Suspends Dosing in Melanoma Trial Due to Quality Issues     6/17/2016
European Commission (EC) Approves the First and Only Immuno-Oncology Combination, Bristol-Myers Squibb (BMY)’s Opdivo (Nivolumab) + Yervoy (Ipilimumab) Regimen, for Treatment of Advanced Melanoma     5/11/2016
Investors Unhappy as Caladrius Biosciences (CLBS) Kills Phase III Oncology Program, Lays Off 40 in SoCal     1/8/2016
Array BioPharma (ARRY) Surges as Binimetinib Meets Goals in Late-Stage Study     12/16/2015
FDA Grants Full U.S. Approval for Novartis AG (NVS)' Targeted Skin Cancer Combo     11/23/2015
FDA Approves Daiichi Sankyo, Plexxikon's Cobimetinib In Combination With Zelboraf for Advanced Melanoma Patients     11/11/2015
FDA Green Lights Genentech (RHHBY)'s Vemurafenib/Cobimetinib Combo for Melanoma     11/10/2015
Investors Elated as Amgen (AMGN) Wins FDA Approval for First-of-Its-Kind Cancer Killing Virus Drug     10/30/2015
Investors Hold Their Breath as Amgen (AMGN) Inches Toward U.S. Approval for Its New Cancer Immunotherapy T-Vec     10/26/2015
Exelixis (EXEL), Genentech (RHHBY)'s Cobimetinib Succeeds in Pivotal Phase III Trial     10/8/2015
FDA Green Lights Bristol-Myers Squibb (BMY)'s Drug Combo for Metastatic Melanoma     10/2/2015
Joining the Anti-PD-L1 Cancer Drug Market, Syndax Inks Deal With Genentech (RHHBY), Closes on $80 Million Series C Round     8/27/2015
Massachusetts' Syndax Banks $80 Million Series C     8/24/2015

News from Around the Web
Genetic Causes Of Higher Melanoma Risk In Men Discovered, Universitat Jaume I de Castellón Reveals     7/22/2016
Microneedle Patch Delivers Localized Cancer Immunotherapy To Melanoma, North Carolina State University Study     3/25/2016
Pharma's Big New Cancer Drug May Be An Old Red Dye     2/26/2016
Vitamin B3 Derivative Cuts Risk Of New Skin Cancers, University of Sydney Study     10/22/2015
Could Laser Skin Test Replace Biopsy For Melanoma? Lancaster University Study     8/24/2015
Coffee Lowers Deadly Skin Cancer Risk, Yale School Of Public Health Study     1/22/2015
Sunscreens Do Not Fully Protect Against Skin Cancer, University Miguel Hernández Study     7/16/2014
Viagra Poses Cancer Risk For Men, JAMA Reveals     6/6/2014
Pine Bark Substance Could Treat Melanoma, Penn State Hershey Melanoma Center Study     5/22/2014
Link Between Viagra And Melanoma Discovered, JAMA Reveals     4/11/2014
Melanoma In Families Linked To Mutations In One Gene, University of Leeds Study     4/3/2014
Sleep Apnea Severity Predicts Aggressiveness of Melanoma, Hospital de Valme Study     9/9/2013
Gene Mutation Immortalizes Malignant Melanoma, University Duisburg-Essen Study     1/28/2013
GlaxoSmithKline (GSK)'s Melanoma Drug May Extend Survival     6/26/2012
GlaxoSmithKline (GSK) Melanoma Drugs May Steal Market From Roche (RHHBY)     5/29/2012

Press Releases
OncoSec Medical Presents Positive Interim Response Data At The Society For Immunotherapy Of Cancer (SITC) Annual Meeting 2016     11/14/2016
Idera Pharma (IDRA) Reports Translational Data Supporting The Mechanism Of Action Of Intratumoral IMO-2125 From Ongoing Phase I Dose Escalation In Clinical Trial In Combination With Ipilimumab In Metastatic Melanoma Patients Refractory To Anti-PD-1 Treatment     11/14/2016
New Study Demonstrates Anti-Tumor Advantages For Combination Treatment Featuring Peregrine (PPHM)’ PS-Targeting Antibodies In A Preclinical Melanoma Model     11/14/2016
Exelixis (EXEL) Announces Presentation Of Cobimetinib Combination Therapy Data At The Society For Melanoma Research 2016 Congress That Support Genentech’s Planned Phase III Pivotal Trials     11/7/2016
Bristol-Myers Squibb Canada (BMY) Release: First-Ever Combination Of Two Immuno-Oncology Agents For Metastatic Melanoma Approved By Health Canada     11/1/2016
The Myriad Genetics (MYGN) myPath Melanoma Test Effectively Diagnosed Patients In The Largest Outcomes-Based Study For A Melanoma Diagnostic     10/27/2016
Delcath Systems (DCTH) Announces First European Clinical Sites For FOCUS Phase 3 Trial For Ocular Melanoma Liver Metastases     10/12/2016
Delcath Systems (DCTH) Announces New U.S. Clinical Sites For FOCUS Phase 3 Trial For Ocular Melanoma Liver Metastases     10/11/2016
Celldex (CLDX) Release: Phase II Study Of Single-Agent Glembatumumab Vedotin In Patients With Checkpoint-Refractory Metastatic Melanoma Meets Primary Overall Response Endpoint And Demonstrates Clinically Meaningful Duration Of Response     10/10/2016
Viralytics Ltd (VLA.AX) Release: CAVATAK YERVOY Combination Demonstrates Promising Clinical Response Rates In Advanced Melanoma     10/10/2016
Incyte (INCY) Release: Additional Phase I Data From ECHO-202 Reinforce Durability Of Response In Patients With Treatment-Naive Advanced Or Metastatic Melanoma Treated With Epacadostat In Combination With Keytruda (Pembrolizumab)     10/7/2016
Q Biomed Comments On Its Glaucoma Drug And Industry News In The Ophthalmology Space     10/7/2016
X4 Pharma Announces Initiation Of Phase Ib Study Of X4P-001 In Patients With Resectable Stage III And Stage IV Melanoma     9/27/2016
Array BioPharma (ARRY) Rockets as Melanoma Drug Meets Endpoint in Phase III Study     9/26/2016
Idera Pharma (IDRA) Reports Promising Data From Ongoing Phase I Dose Escalation In Clinical Trial Of Intra-Tumoral IMO-2125 In Combination With Ipilimumab In Patients With PD-1 Refractory Metastatic Melanoma     9/26/2016

//-->